Last updated: 2026-09-06 06:39:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Vor Biopharma Inc. (VOR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $25.06, with a market capitalisation of $1.46B and a P/E ratio of 2.28. Over the past 52 weeks, its price has ranged from $6.50 to $49.95. This page covers its latest market performance, valuation, price trends and company information.
$1.46B | |
$24.17 | |
$1,272.40 | |
$2.62 | |
$24.24 | |
374.43K | |
-- | |
2.28 | |
$49.95 | |
$6.50 | |
-- | |
-- |
Vor Biopharma Inc. (VOR) last closed at $24.24 as of 2026-09-04 23:57:00, unchanged from the previous close of $24.24.
During the latest regular trading session, VOR traded between $2.62 and $1,272.40, with a volume of 374.43K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Vor Biopharma Inc. (VOR) moved from $22.50 to $25.06, representing a gain of 11.38% ($2.56).
The stock traded between $24.06 and $25.17 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 622.00 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 42.7%
VOR is currently trading at $25.06, placing it 42.7% of the way from its 52-week low of $6.50 to its 52-week high of $49.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 76 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vor Biopharma Inc. (VOR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.